A rare case: evaluation of chronic hypoklemia in patient with Gitelman syndrome
DOI:
https://doi.org/10.18203/2349-3933.ijam20233569Keywords:
Gitelman syndrome, HypokalemiaAbstract
Gitelman syndrome (GS) is inherited in a recessive manner and is caused by inactivating mutations in the SLC12A3 gene characterized by the loss of salt, leading to hypokalemic metabolic alkalosis with concurrent hypomagnesemia and hypocalciuria. Hypokalemia is defined as a plasma potassium concentration of less than 3.5 mmol/l. A 24-year-old woman came with weakness and numbness in both lower limbs for the past 1 day and later extended to all four extremities. This patient had been admitted to hospital twice in the last 2 months with similar complaints. Laboratory results showed hypokalemia, hypocalcemia, hypomagnesemia, and metabolic alkalosis accompanied by elevated eGFR, anemia and increased potassium secretion in the distal tubules. Gitelman syndrome is the rare case and does not have specific symptoms, so the diagnosis depends on the accuracy of high clinical suspicion, especially those experiencing hypokalemia.
Metrics
References
Merwe PD, Rensburg MA, haylett WL, Bardien S, davids MR. Gitelman syndrome in a South African family presenting with hypokalaemia andunusual food cravings. BMC Nephrol. 2017;18:38:1-8.
Urwin S, Willows J, Sayer JA. The challenges of diagnosis and management of Gitelman syndrome. Clin Endocrinol (Oxf). 2020;92(1):3-10.
Blanchard A, Bockenhauer D, Bolignano D, Calo LA, Cosyns E, devuyst O, et al. Gitelman syndrome: consensus and guidance froma Kidney Disease: Improving Global Outcomes(KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24-33.
Nessa L, Singh A, Sharif MW, Enabi J, Bashir M. Diagnostic Challenge of Gitelman Syndrome: A Rare but Significant Cause of Electrolyte Imbalance. J Clini Nephrol. 2023;7:53-6.
Kokko JP. Cecil Textbook of Medicine. In: Goldman L, Ausiello D, editors. Fluids and Electrolytes. 22nd ed. Philadelphia: Saunders. 2004;683-5.
Anthony J, Niah W, Potassium Disorder: Hypokalemia and Hyperkalemia. Am Fam Phys. 2015;92(6):487-91.
Umami V, Oktavia D, Kunmartini S, Wibisana D, Siregar P. Diagnosis and Clinical Approach in Gitelman Syndrome. Acta Med Indones. 2011;43(1):53-8.
Lin SH. Laboratory test to determine the cause of hypokalemia and paralysis. Arch Intern Med. 2004;164:1561-6.
Groeneveld J, Sijpkens Y, Lin S. An approach to the patient with severe hypokalemia: the potassium quiz. Q J Med. 2005;98:305.
Unwin RJ, Luft CF, Shirley DG. Pathophysiology and Management of Hypokalemia: a clinical perspective. J Nat Rev Nephrol. 2011;7(2):75-84.
Kurtz I. Molecular pathogenesis of Bartter’s and Gitelman’s syndromes. Kidney Int. 2018;54:1396.
Cruz DN, Shaer AJ, Bia MJ. Gitelman’s syndrome revisited: An evaluation of symptoms and health-related quality of life. Kidney Int. 2021;59:710.
Cruz DN, Simon DB, Nelson-Williams C. Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension. 2011;37:1458.
Urwin S, Willows J, Sayer JA. The challenges of diagnosis and management of Gitelman syndrome. Clin Endocrinol (Oxf). 2020;92:3-10.
Graziani G, Fedeli C, Moroni L, Cosmai L, Badalamenti S, Ponticelli C. Gitelman syndrome: pathophysiological and clinical aspects. QJM. 2010;103(10):741-8.
Colussi G, Rombola G, De Ferrari ME. Correction of hypokalemia with antialdosterone therapy in Gitelman’s syndrome. Am J Nephrol. 2004;14:127.
Griffing GT, Komanicky P, Aurecchia SA. Amiloride in Bartter’s syndrome. Clin Pharmacol Ther. 2012;31:713.
Bockenhauer D. Bartters Syndrome. National Organization for Rare Disorder (NORD). 2016. Available at: http://raredisease.org/rare-disease/ bartters-syndrome/. Accessed on 09 September 2023.
Downloads
Published
How to Cite
Issue
Section
